VIDEO: Biomarker testing critically important for patients with metastatic lung cancer
Click Here to Manage Email Alerts
In this video, Nathan A. Pennell, MD, PhD, highlighted a presentation from the virtual ASCO Annual Meeting, which looked at trends in molecular testing among patients with metastatic lung cancer in the U.S.
When restricting biomarker testing to EGFR, ALK, BRAF, ROS and PDL-1, the findings showed that less than half of those eligible are receiving molecular testing and even less are receiving next-generation sequencing.
“We actually have highly effective treatments that can help patients with metastatic lung cancer live for years with minimal side effects,” Pennell, medical oncologist at the Cleveland Clinic and associate professor medical oncology at the Cleveland Clinic Lerner College, said. “But you have to test for them.”
Collapse
Healio Interview; Robert N, et al. Abstract 9004. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Read more about
Click Here to Manage Email Alerts